TrialPsychopharmacology2020

A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects.

Deborah A Yurgelun-Todd et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.